Dr. Spelsberg has significant experience in a variety of management positions. Before joining ODU, he was a member of the Management Board of TIB Chemicals AG and a member of the Advisory Board of Günther Spelsberg GmbH & Co. KG. Throughout his career, he has held positions in corporate development, commercial management and as a management consultant. An industrial engineer by training, Dr. Spelsberg brings to the task extensive know-how and valuable experience.
In his new role, Dr. Spelsberg will be responsible for worldwide Sales, Portfolio Management, Corporate Communications & Marketing as well as Automotive. Together with Managing Directors Robert Klemisch and Dr. Josef Leitner, he will guide the company's future development according to this principle: The management team will actively shape the future of ODU with creativity, inventiveness and innovative strength, and thereby continue to focus on upholding these values for employees, customers and partners.
“We’re confident that, thanks to his extensive experience and knowledge, Dr. Spelsberg will make a significant contribution to the constructive and positive development of ODU. ODU stands for consistency, know-how and quality, and we take pride in offering our products as an enrichment to, and an integral part of, a variety of industries,” says Dr. Christoph Endrös, spokesman for the shareholders.
In the context of these changes, Dr.-Ing. Kurt Woelfl will join the ODU Supervisory Board, replacing Dr. Christoph Endrös. “ODU has done extremely well under his leadership – from a turnover of about 70 million euros in 2007 to 300 million euros today. His strategic decisions have enabled the company to establish a strong position in the medical, military and test and measurement markets, including the automotive sector, in Europe, North America and Asia. ODU now has five production sites and twelve sales offices worldwide,” says Dr. Christoph Endrös.
Dr. Christoph Endrös is retiring from the Supervisory Board after serving for many years as its chairman. He will now chair the in 2024 newly created Shareholder’s Committee. Dr. Stefan Gilch will take over as Chairman of the Supervisory Board. Dr. Ralph Lässig, who has been a member since January 2023, continuous to serve as member of the Supervisory Board.